Celiac disease is not a risk factor for infertility in men.

Cancer Epidemiology Unit, Center for Experimental Research and Medical Studies and Center for Oncologic Prevention in Piedmont, University of Turin, Turin, Italy.
Fertility and sterility (Impact Factor: 4.3). 02/2011; 95(5):1709-13.e1-3. DOI: 10.1016/j.fertnstert.2011.01.132
Source: PubMed

ABSTRACT To examine fertility in men with biopsy-verified celiac disease (CD) in light of research that suggests that men with CD have impaired sperm quality.
Using multinomial logistic regression and Cox regression, we estimated the fertility of the study group compared with that of 31,677 age-matched reference male controls.
Swedish nationwide population-based cohort of 7,121 men with CD (defined according to duodenal-jejunal biopsy data with [Marsh III] villous atrophy) ages 18-54 years at some point before the end of follow-up.
Number of children according to the Swedish Multi-Generation Register.
During follow-up, men with CD had 9,935 children compared with 42,245 among controls. Adjusting for age, calendar period, and parity and stratifying by education, the overall fertility hazard ratio in the men with biopsy-verified CD was 1.02 (95% confidence interval, 0.99-1.04).
This study found a normal fertility in men with diagnosed CD.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Celiac disease (CD) is a lifelong disorder. Patients are at increased risk of complications and comorbidity. We conducted a review of the literature on patient support and information in CD and aim to issue recommendations about patient information with regards to CD. We searched PubMed for English-language articles published between 1900 and June 2014, containing terms related to costs, economics of CD, or education and CD. Papers deemed relevant by any of the participating authors were included in the study. No quantitative synthesis of data was performed. Instead we formulated a consensus view of the information that should be offered to all patients with CD. There are few randomized clinical trials examining the effect of patient support in CD. Patients and their families receive information from many sources. It is important that health care personnel guide the patient through the plethora of facts and comments on the Internet. An understanding of CD is likely to improve dietary adherence. Patients should be educated about current knowledge about risk factors for CD, as well as the increased risk of complications. Patients should also be advised to avoid other health hazards, such as smoking. Many patients are eager to learn about future non-dietary treatments of CD. This review also comments on novel therapies but it is important to stress that no such treatment is available at present. Based on mostly observational data, we suggest that patient support and information should be an integral part of the management of CD, and is likely to affect the outcome of CD.
    12/2014; 3(2). DOI:10.1177/2050640614562599
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to dissect the autoantibody response in celiac disease (CD) that remains largely unknown, with the goal of identifying the disease-specific autoantigenic protein pattern or the so called epitome. Sera from CD patients were used to select immunoreactive antigens from a cDNA phage-display library. Candidate genes were identified, the corresponding proteins produced and their immunoreactivity validated with sera from CD patients and controls. Thirteen CD-specific antigens were identified and further validated by protein microarray. The specificity for 6 of these antigens was confirmed by ELISA. Furthermore we showed that this antibody response was not abolished on a gluten free diet and was not shared with other autoimmune diseases. These antigens appear to be CD specific and independent of gluten induction. The utility of this panel extends beyond its diagnostic value and it may drive the attention to new targets for unbiased screens in autoimmunity research.
    Clinical Immunology 04/2013; 148(1):99-109. DOI:10.1016/j.clim.2013.04.009 · 3.99 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The diagnosis of coeliac disease has advanced in the past decade owing to increased clinical awareness and improved tests. Coeliac disease is now regarded as a common disease presenting at any age with a broad spectrum of symptoms. Previous guidelines on diagnosis relied on the histological analysis of duodenal biopsy samples. However, contemporary antibody analysis is a diagnostic tool with a comparatively high accuracy that has reduced reliance on performing biopsies. Furthermore, determination of HLA-based genetic susceptibility to coeliac disease has become routine. European and North American guidelines utilize symptoms, coeliac antibodies (primarily tissue transglutaminase 2 IgA and endomysial IgA antibodies), HLA determination and histological analysis of biopsy tissue for diagnosis. Some guidelines conclude that the diagnostic accuracy of tissue transglutaminase 2 IgA antibodies is sufficient to omit duodenal biopsies in selected children with very high antibody levels, in the presence of clear symptom response as well as a positive endomysial antibody test and confirmation of genetic susceptibility. This Review discusses if such a strategy is appropriate for children and adults in all populations. The performance characteristics of antibody tests (particularly of the tissue transglutaminase 2 IgA test) including quality control and characterisation of the population in whom testing is performed are also discussed.
    Nature Reviews Gastroenterology &#38 Hepatology 09/2014; 11(11). DOI:10.1038/nrgastro.2014.162 · 10.81 Impact Factor